Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation generative artificial intelligence technologies for drug discovery and biomarker development.

Under his leadership, Insilico raised over $400 million in multiple rounds from expert investors, opened R&D centers in six countries or regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions, nominated over 15 preclinical candidates, and entered human clinical trials with AI-discovered novel target and AI-designed novel molecule. Since 2015 he has invented critical technologies in the field of generative artificial intelligence and reinforcement learning (RL) for generation of novel molecular structures with the desired properties and generation of synthetic biological and patient data. Since 2012 he published over 160 peer-reviewed research papers and 2 books.

He founded and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (9th annual in 2022), the world's largest event on aging in the pharmaceutical industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.